1 of 1
Story summary
- Under U.S. President Donald Trump’s term, pharmaceutical companies are increasing lobbying expenditures, led by Checkmate Government Relations, Miller Strategies, and Ballard Partners.
- In 2025, those firms earned $11.7 million from pharmaceutical clients, up from $2.2 million in 2024.
- This lobbying surge coincides with 16 companies signing drug pricing deals with the White House.
- Merck is restructuring its pharmaceutical unit to address Keytruda sales declines ahead of its 2028 patent expiration.
